Translational biology of osteosarcoma

Nature Reviews Cancer

Volumn 14, Issue 11, 2014, Pages 722-735

  Kansara, Maya ^a,b   Teng, Michele W ^c,d   Smyth, Mark J ^c,d   Thomas, David M ^a,b,e  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH RECEPTOR; PROTEIN TYROSINE KINASE; ANTINEOPLASTIC AGENT;

BONE DEVELOPMENT; EPIGENETICS; GENETIC ASSOCIATION; HEDGEHOG; HUMAN; IMMUNOCOMPETENT CELL; INTRACELLULAR SIGNALING; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOSARCOMA; REVIEW; SOMATIC CELL GENETICS; WNT SIGNALING PATHWAY; ANIMAL; GENETICS; IMMUNOLOGY; TRANSLATIONAL RESEARCH;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE DEVELOPMENT; HUMANS; OSTEOSARCOMA; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84908156415     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3838     Document Type: Review

References (201)

1. WHO. WHO Classification of Tumours of Soft Tissue and Bone. 4th Edn, 281-295 (International Agency for Research on Cancer, 2013).
2. Bernthal, N. M. et al. Long-term results (25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer 118, 5888-5893 (2012).
3. Link, M. P. et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N. Engl. J. Med. 314, 1600-1606 (1986).
4. Jaffe, N. et al. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N. Engl. J. Med. 291, 994-997 (1974).
5. Collins, M. et al. Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J. Clin. Oncol. 31, 2303-2312 (2013).
6. Meyers, P. A. et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. Cancer 117, 1736-1744 (2011).
7. Grabowski, P. Physiology of bone. Endocr. Dev. 16, 32-48 (2009).
8. Wang, D. et al. Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J. Bone Miner. Res. 14, 893-903 (1999).
9. Gronthos, S. et al. Differential cell surface expression of the STRO-1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells. J. Bone Miner. Res. 14, 47-56 (1999).
10. Mutsaers, A. J. & Walkley, C. R. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? Bone 62, 56-63 (2014).
11. Roodman, G. D. Cell biology of the osteoclast. Exp. Hematol. 27, 1229-1241 (1999).
12. Kaji, H. et al. Insulin-like growth factor-I mediates osteoclast-like cell formation stimulated by parathyroid hormone. J. Cell. Physiol. 172, 55-62 (1997).
13. Varghese, J. S. & Easton, D. F. Genome-wide association studies in common cancers-what have we learnt? Curr. Opin. Genet. Dev. 20, 201-209 (2010).
14. Savage, S. A. et al. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nature Genet. 45, 799-803 (2013).
15. Skerry, T. M. The response of bone to mechanical loading and disuse: fundamental principles and influences on osteoblast/osteocyte homeostasis. Arch. Biochem. Biophys. 473, 117-123 (2008).
16. Chang, H. J. et al. Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin. Cancer Res. 11, 3288-3295 (2005).
17. Karlsson, E. K.et al.Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B. Genome Biol. 14, R132 (2013).
18. Molyneux, S. D.et al. Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J. Clin. Invest. 120, 3310-3325 (2010).
19. Vahle, J. L.et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol. Pathol. 32, 426-438 (2004).
20. Szymanska, J. et al. Ring chromosomes in parosteal osteosarcoma contain sequences from 12q13-15: a combined cytogenetic and comparative genomic hybridization study. Genes Chromosomes Cancer 16, 31-34 (1996).
21. Lau, C. C. et al.Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer 39, 11-21 (2004).
22. Bayani, J. et al. Genomic mechanisms and measurement of structural and numerical instability in cancer cells. Semin. Cancer Biol. 17, 5-18 (2007).
23. Chen, X. et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 7, 104-112 (2014).
24. Atiye, J. et al. Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer 42, 158-163 (2005).
25. Sadikovic, B. et al. Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum. Mol. Genet. 18, 1962-1975 (2009).
26. Kuijjer, M. L.et al. Genome-wide analyses on high-grade osteosarcoma: making sense of a genomically most unstable tumor. Int. J. Cancer 133, 2512-2521 (2013).
27. Wunder, J. S.et al. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J. Clin. Oncol. 23, 1483-1490 (2005).
28. Toguchida, J. et al. Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma. Nature 338, 156-158 (1989).
29. Cesare, A. J. & Reddel, R. R. Alternative lengthening of telomeres: models, mechanisms and implications. Nature Rev. Genet. 11, 319-330 (2010).
30. Scheel, C. et al. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene 20, 3835-3844 (2001).
31. Stephens, P. J. et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144, 27-40 (2011).
32. Sowa, Y. et al. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem. Biophys. Res. Commun. 241, 142-150 (1997).
33. Watanabe, K. et al. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ. 12, 10-18 (2005).
34. Capobianco, E. et al. Separate and Combined Effects of DNMT and HDAC Inhibitors in Treating Human Multi-Drug Resistant Osteosarcoma HosDXR150 Cell Line. PLoS ONE 9, e95596 (2014).
35. Li, Y. et al. Enhancement of radiosensitivity by 5-Aza-CdR through activation of G2/M checkpoint response and apoptosis in osteosarcoma cells. Tumour Biol. 35, 4831-4839 (2014).
36. Quinn, J. M. et al. Transforming growth factor β affects osteoclast differentiation via direct and indirect actions. J. Bone Miner. Res. 16, 1787-1794 (2001).
37. Dougall, W. C. et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412-2424 (1999).
38. Lee, J. A. et al. RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatr. Blood Cancer 56, 738-743 (2011).
39. Rousseau, J. et al. Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. J. Bone Miner. Res. 26, 2452-2462 (2011).
40. Ory, B. et al. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104, 2522-2529 (2005).
41. Heymann, D. et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 37, 74-86 (2005).
42. Ohba, T. et al. Pleiotropic effects of bisphosphonates on osteosarcoma. Bone 63, 110-120 (2014).
43. Berger, M. et al. 153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. Ann. Oncol. 23, 1899-1905 (2012).
44. Kelleher, F. C. et al. Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. Pharmacol. Ther. 136, 153-168 (2012).
45. Yang, W. et al. Targeting hedgehog-GLI-2 pathway in osteosarcoma. J. Orthop. Res. 31, 502-509 (2013).
46. Lo, W. W. et al. Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma. Cancer 120, 537-547 (2014).
47. Mu, X. et al. Notch signaling is associated with ALDH activity and an aggressive metastatic phenotype in murine osteosarcoma cells. Front. Oncol. 3, 143 (2013).
48. Kolb, E. A. et al. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatr. Blood Cancer 58, 815-818 (2012).
49. Vijayakumar, S. et al. High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A. Cancer Cell 19, 601-612 (2011).
50. Cai, Y. et al. Wnt pathway in osteosarcoma, from oncogenic to therapeutic. J. Cell Biochem. 115, 625-631 (2014).
51. Lin, C. H. et al. Dkk-3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma. Sarcoma 2013, 147541 (2013).
52. Kansara, M. et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 119, 837-851 (2009).
53. Rubin, E. M. et al. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol. Cancer Ther. 9, 731-741 (2010).
54. Yu, X. W. et al. Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis. Tumour Biol. 35, 155-160 (2014).
55. Grignani, G. et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann. Oncol. 23, 508-516 (2012).
56. Sulzbacher, I. et al. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod. Pathol. 16, 66-71 (2003).
57. Tanaka, T. et al. Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy. Clin. Exp. Metastasis 30, 369-379 (2013).
58. Liu, Y. et al. Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies. Tumour Biol. http://dx.doi.org/10.1007/s13277-014-2165-9 (2014).
59. Gorlick, R. et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J. Clin. Oncol. 17, 2781-2788 (1999).
60. Kilpatrick, S. E. et al. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod. Pathol. 14, 1277-1283 (2001).
61. Ebb, D. et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J. Clin. Oncol. 30, 2545-2551 (2012).
62. Pollak, M. N. et al. Insulinlike growth factor I: a potent mitogen for human osteogenic sarcoma. J. Natl Cancer Inst. 82, 301-305 (1990).
63. Kuijjer, M. L. et al. IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer 13, 245 (2013).
64. Houghton, P. J. et al. Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr. Blood Cancer 54, 921-926 (2010).
65. Weigel, B. et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr. Blood Cancer 61, 452-456 (2014).
66. MacEwen, E. G. et al. c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells. Clin. Exp. Metastasis 20, 421-430 (2003).
67. Sampson, E. R. et al. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J. Bone Miner. Res. 26, 1283-1294 (2011).
68. Hingorani, P. et al. Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo. Clin. Cancer Res. 15, 3416-3422 (2009).
69. Spreafico, A. et al. Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells. FASEB J. 22, 1560-1571 (2008).
70. Liu, P. Y. et al. Inhibitory effect and significance of rapamycin on the mammalian target of rapamycin signaling pathway in osteosarcoma stem cells and osteosarcoma cells. Zhonghua Zhong Liu Za Zhi 35, 175-180 (2013).
71. Chawla, S. P. et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J. Clin. Oncol. 30, 78-84 (2012).
72. Demetri, G. D. et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J. Clin. Oncol. 31, 2485-2492 (2013).
73. Pignochino, Y. et al. The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin. Cancer Res. 19, 2117-2131 (2013).
74. Saeki, T. et al. Physiological and oncogenic Aurora-A pathway. Int. J. Biol. Sci. 5, 758-762 (2009).
75. Tavanti, E. et al. Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. Br. J. Cancer 109, 2607-2618 (2013).
76. Zhu, X. P. et al. Inhibition of Aurora-B suppresses osteosarcoma cell migration and invasion. Exp. Ther. Med. 7, 560-564 (2014).
77. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
78. Schreiber, R. D. et al. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
79. Zitvogel, L. et al. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nature Rev. Immunol. 6, 715-727 (2006).
80. Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999).
81. Takayanagi, H. et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature 416, 744-749 (2002).
82. Franzoso, G. et al. Requirement for NF-κB in osteoclast and B-cell development. Genes Dev. 11, 3482-3496 (1997).
83. Takayanagi, H. et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature 408, 600-605 (2000).
84. Lorenzo, J. et al. Osteoimmunology. Immunol. Rev. 208, 5-6 (2005).
85. Lorenzo, J. et al. Osteoimmunology: interactions of the bone and immune system. Endocr. Rev. 29, 403-440 (2008).
86. Coley, W. B. I.I. Contribution to the Knowledge of Sarcoma. Ann. Surg. 14, 199-220 (1891).
87. Coley, W. B. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc. R. Soc. Med. 3, 1-48 (1910).
88. Eilber, F. R. et al. Osteosarcoma. Results of treatment employing adjuvant immunotherapy. Clin Orthop Relat Res, 94-100 (1975).
89. Karbach, J. et al. Phase I clinical trial of mixed bacterial vaccine (Coley's toxins) in patients with NY-ESO-1 expressing cancers: immunological effects and clinical activity. Clin. Cancer Res. 18, 5449-5459 (2012).
90. Jeys, L. M. et al. Post operative infection and increased survival in osteosarcoma patients: are they associated? Ann. Surg. Oncol. 14, 2887-2895 (2007).
91. Zitvogel, L. et al. Immunological aspects of cancer chemotherapy. Nature Rev. Immunol. 8, 59-73 (2008).
92. Moore, C. et al. Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. Pediatr. Blood Cancer 55, 1096-1102 (2010).
93. Schroit, A. J. & Fidler, I. J. Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res. 42, 161-167 (1982).
94. Kleinerman, E. S. et al. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J. Clin. Oncol. 10, 1310-1316 (1992).
95. Sone, S. et al. Potentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytes. J. Immunol. 132, 2105-2110 (1984).
96. Kansara, M. et al. Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation. J. Clin. Invest. 123, 5351-5360 (2013).
97. MacEwen, E. G. et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J. Natl Cancer Inst. 81, 935-938 (1989).
98. Meyers, P. A. et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J. Clin. Oncol. 26, 633-638 (2008).
99. Chou, A. J. et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. Cancer 115, 5339-5348 (2009).
100. Johal, S. et al. Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis. Value Health 16, 1123-1132 (2013).
101. Kosmidis, P. A. et al. The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alfa-2b. J. Clin. Oncol. 10, 1153-1157 (1992).
102. Beresford, J. N. et al. Interferons and bone. A comparison of the effects of interferon-α and interferon-γ in cultures of human bone-derived cells and an osteosarcoma cell line. Eur. J. Biochem. 193, 589-597 (1990).
103. Yuan, X. W. et al. Interferon-α enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis. Acta Pharmacol. Sin. 28, 1835-1841 (2007).
104. Masuda, S. et al. Antitumor effect of human leukocyte interferon on human osteosarcoma transplanted into nude mice. Eur. J. Cancer Clin. Oncol. 19, 1521-1528 (1983).
105. Strander, H. et al. Adjuvant interferon treatment in human osteosarcoma. Cancer Treat. Res. 62, 29-32 (1993).
106. Strander, H. Interferons and osteosarcoma. Cytokine Growth Factor Rev. 18, 373-380 (2007).
107. Bielack, S. S. et al. MAP plus maintenance pegylated interferon α-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 "good response" randomization. 2013 ASCO Annual Meeting, Abstract LBA10504 (2014).
108. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
109. Kroemer, G. et al. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51-72 (2013).
110. Zitvogel, L. et al. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 39, 74-88 (2013).
111. Champiat, S. et al. Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. Oncoimmunology 3, e27817 (2014).
112. van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439-442 (2013).
113. He, J. et al. Association between CTLA-4 genetic polymorphisms and susceptibility to osteosarcoma in Chinese Han population. Endocrine. 45, 325-330 (2014).
114. Liu, Y. et al. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma. DNA Cell Biol. 30, 1051-1055 (2011).
115. Nagamori, M. et al. Intrinsic and extrinsic manipulation of B7/CTLA-4 interaction for induction of anti-tumor immunity against osteosarcoma cells. Anticancer Res. 22, 3223-3227 (2002).
116. Kawano, M. et al. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma. Oncol. Rep. 29, 1001-1006 (2013).
117. Kozawa, E. et al. Suppression of tumour metastasis in a murine osteosarcoma model with anti-CD25 monoclonal antibody treatment. Anticancer Res. 30, 5019-5022 (2010).
118. Zitvogel, L. & Kroemer, G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 1, 1223-1225 (2012).
119. Lussier, D. M. et al. 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC) 162 (Society for Immunotherapy of Cancer, 2013).
120. Paget, C. et al. Studying the role of the immune system on the antitumor activity of a Hedgehog inhibitor against murine osteosarcoma. Oncoimmunology 1, 1313-1322 (2012).
121. Melero, I. et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature Med. 3, 682-685 (1997).
122. Gorlick, R. et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin. Cancer Res. 9, 5442-5453 (2003).
123. Bunnell, B. A. et al. New concepts on the immune modulation mediated by mesenchymal stem cells. Stem Cell Res. Ther. 1, 34 (2010).
124. Ishida, H. et al. Expression of the SART1 tumor-rejection antigen in human osteosarcomas. Int. J. Oncol. 17, 29-32 (2000).
125. Tsuda, N. et al. Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides. J. Orthop. Res. 19, 346-351 (2001).
126. Tsukahara, T. et al. Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma. Cancer Sci. 99, 368-375 (2008).
127. Jacobs, J. F. et al. Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int. J. Cancer 120, 67-74 (2007).
128. Rainusso, N. et al. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther. 19, 212-217 (2012).
129. Navid, F. et al. Anti-GD2 antibody therapy for GD2-expressing tumors. Curr. Cancer Drug Targets 10, 200-209 (2010).
130. Shibuya, H. et al. Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. Cancer Sci. 103, 1656-1664 (2012).
131. Ahmed, M. & Cheung, N. K. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 588, 288-297 (2014).
132. Tarek, N. et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J. Clin. Invest. 122, 3260-3270 (2012).
133. Gorlick, R. et al. Children's Oncology Group's 2013 blueprint for research: bone tumors. Pediatr. Blood Cancer 60, 1009-1015 (2013).
134. Yang, R. et al. The folate receptor α is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin. Cancer Res. 13, 2557-2567 (2007).
135. Schiano, C. et al. Different expression of CD146 in human normal and osteosarcoma cell lines. Med. Oncol. 29, 2998-3002 (2012).
136. Joyama, S. et al. Dendritic cell immunotherapy is effective for lung metastasis from murine osteosarcoma. Clin. Orthop. Relat. Res. 453, 318-327 (2006).
137. Chauvin, C. et al. Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. Cancer Res. 68, 9433-9440 (2008).
138. Himoudi, N. et al. Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. Clin. Transl. Oncol. 14, 271-279 (2012).
139. Schwinger, W. et al. Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients. Ann. Oncol. 16, 1199-1206 (2005).
140. Worth, L. L. et al. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin. Cancer Res. 6, 3713-3718 (2000).
141. Zhou, Z. et al. Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity. Mol. Cancer Res. 3, 685-691 (2005).
142. Lafleur, E. A. et al. Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells. Cancer Res. 61, 4066-4071 (2001).
143. Igney, F. H. & Krammer, P. H. Immune escape of tumors: apoptosis resistance and tumor counterattack. J. Leukoc. Biol. 71, 907-920 (2002).
144. Gordon, N. & Kleinerman, E. S. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Cancer Treat. Res. 152, 497-508 (2009).
145. Koshkina, N. V. et al. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol. Cancer Res. 5, 991-999 (2007).
146. Postiglione, L. et al. Effect of human granulocyte macrophage-colony stimulating factor on differentiation and apoptosis of the human osteosarcoma cell line SaOS-2. Eur. J. Histochem. 47, 309-316 (2003).
147. Arndt, C. A. et al. Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group. Clin. Cancer Res. 16, 4024-4030 (2010).
148. Huang, M. et al. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol. Sci. 35, 41-50 (2014).
149. Rahman, N. Realizing the promise of cancer predisposition genes. Nature 505, 302-308 (2014).
150. Brown, S. D. et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 24, 743-750 (2014).
151. Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nature Med. 19, 747-752 (2013).
152. Hacohen, N. et al. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol. Res. 1, 11-15 (2013).
153. Pritchard-Jones, K. et al. Cancer in children and adolescents in Europe: developments over 20 years and future challenges. Eur. J. Cancer 42, 2183-2190 (2006).
154. Cotterill, S. J. et al. Stature of young people with malignant bone tumors. Pediatr. Blood Cancer 42, 59-63 (2004).
155. Logue, J. P. & Cairnduff, F. Radiation induced extraskeletal osteosarcoma. Br. J. Radiol. 64, 171-172 (1991).
156. Le Vu, B. et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int. J. Cancer 77, 370-377 (1998).
157. Seton, M. Paget disease of bone: diagnosis and drug therapy. Cleve Clin. J. Med. 80, 452-462 (2013).
158. Smith, J. et al. Bone sarcomas in Paget disease: a study of 85 patients. Radiology 152, 583-590 (1984).
159. Laurin, N. et al. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am. J. Hum. Genet. 70, 1582-1588 (2002).
160. Srivastava, S. et al. Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53. Oncogene 8, 2449-2456 (1993).
161. Gokgoz, N. et al. Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer 92, 2181-2189 (2001).
162. Hansen, M. F. et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc. Natl Acad. Sci. USA 82, 6216-6220 (1985).
163. Larsen, N. B. & Hickson, I. D. RecQ Helicases: Conserved Guardians of Genomic Integrity. Adv. Exp. Med. Biol. 767, 161-184 (2013).
164. Wang, L. L. et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J. Natl Cancer Inst. 95, 669-674 (2003).
165. Wang, L. L. et al. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am. J. Med. Genet. 102, 11-17 (2001).
166. Rosen, R. S. et al. Werner's syndrome. Br. J. Radiol. 43, 193-198 (1970).
167. Lauper, J. M. et al. Spectrum and risk of neoplasia in Werner syndrome: a systematic review. PLoS ONE 8, e59709 (2013).
168. German, J. Bloom's syndrome. XX. The first 100 cancers. Cancer Genet. Cytogenet. 93, 100-106 (1997).
169. Siitonen, H. A. et al. Molecular defect of RAPADILINO syndrome expands the phenotype spectrum of RECQL diseases. Hum. Mol. Genet. 12, 2837-2844 (2003).
170. Lonardo, F. et al.p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer 79, 1541-1547 (1997).
171. Colombo, E. A. et al. Novel physiological RECQL4 alternative transcript disclosed by molecular characterisation of Rothmund-Thomson Syndrome sibs with mild phenotype. Eur. J. Hum. Genet. http://dx.doi.org/10.1038/ejhg.2014.18 (2014).
172. Maire, G. et al. Recurrent RECQL4 imbalance and increased gene expression levels are associated with structural chromosomal instability in sporadic osteosarcoma. Neoplasia 11, 260-268, (2009).
173. Oh, J. H. et al. Aberrant methylation of p14ARF gene correlates with poor survival in osteosarcoma. Clin. Orthop. Relat. Res. 442, 216-222 (2006).
174. Sonaglio, V. et al. Aberrant DNA methylation of ESR1 and p14ARF genes could be useful as prognostic indicators in osteosarcoma. Onco Targets Ther. 6, 713-723 (2013).
175. Tsuchiya, T. et al. Analysis of the p16INK4, 14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet. Cytogenet. 120, 91-98 (2000).
176. Hou, P. et al. Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer 106, 1602-1609 (2006).
177. Entz-Werle, N. et al. Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis. Neoplasia 9, 678-688 (2007).
178. Mendoza, S. et al. Allelic loss at 10q26 in osteosarcoma in the region of the BUB3 and FGFR2 genes. Cancer Genet. Cytogenet. 158, 142-147 (2005).
179. Kresse, S. H. et al. LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization. Genes Chromosomes Cancer 48, 679-693 (2009).
180. Yen, C. C. et al. Identification of chromosomal aberrations associated with disease progression and a novel 3q13.31 deletion involving LSAMP gene in osteosarcoma. Int. J. Oncol. 35, 775-788 (2009).
181. Yang, J. et al. Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma. Cancer Lett. 291, 31-38 (2010).
182. Freeman, S. S. et al. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 113, 1453-1461 (2008).
183. Chen, W. et al. Epigenetic and genetic loss of Hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell 6, 387-398 (2004).
184. Rathi, A. et al. Aberrant methylation of the HIC1 promoter is a frequent event in specific pediatric neoplasms. Clin. Cancer Res. 9, 3674-3678 (2003).
185. Li, Y. et al. Epigenetic regulation of the pro-apoptosis gene TSSC3 in human osteosarcoma cells. Biomed. Pharmacother. 68, 45-50 (2014).
186. Lim, S. et al. Inactivation of the RASSF1A in osteosarcoma. Oncol. Rep. 10, 897-901 (2003).
187. Al-Romaih, K. et al. Decitabine-induced demethylation of 5' CpG island in GADD45A leads to apoptosis in osteosarcoma cells. Neoplasia 10, 471-480 (2008).
188. Kresse, S. H. et al. Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma. PLoS ONE 7, e48262 (2012).
189. Wei, G. et al. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int. J. Cancer 80, 199-204 (1999).
190. Yotov, W. V.et al. Amplifications of DNA primase 1 (PRIM1) in human osteosarcoma. Genes Chromosomes Cancer 26, 62-69 (1999).
191. Entz-Werle, N. et al. Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. Int. J. Cancer 117, 349-355 (2005).
192. van Dartel, M. et al. Amplification of 17p11.2 approximately p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma. Cancer Genet. Cytogenet. 139, 91-96 (2002).
193. Yang, J. et al. Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma. BMC Med. Genom. 6, 56 (2013).
194. Yang, J. et al. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer 117, 4925-4938 (2011).
195. Lu, X. Y.et al. Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma. Mol. Cancer Res. 6, 937-946 (2008).
196. Lockwood, W. W. et al. Cyclin E1 is amplified and overexpressed in osteosarcoma. J. Mol. Diagn. 13, 289-296 (2011).
197. Yan, T. et al. COPS3 amplification and clinical outcome in osteosarcoma. Cancer 109, 1870-1876 (2007).
198. Li, Y. et al. Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. Exp. Mol. Pathol. 84, 234-239 (2008).
199. Ulaner, G. A. et al.Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum. Mol. Genet. 12, 535-549 (2003).
200. Anderson, P. M. et al. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatr. Blood Cancer 61, 238-244 (2014).
201. Strander, H. et al. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol. 34, 877-880 (1995).